On February 28, 2020 NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, reported its unaudited annual revenues for Q4 and the unaudited revenues for the year ended December 31, 2019 (Press release, Nanobiotix, FEB 28, 2020, View Source [SID1234555004]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Activity and results
Nanobiotix’s revenue for the fourth quarter amounted to approximatively €20k.
Most of the revenues generated by the Company during this period result from the recharge of costs related to our license and collaboration agreement with PharmaEngine.
Overall, Nanobiotix’s annual revenue in 2019 amounted to approximatively €68k.
The amount of cash and cash equivalent as of December 31st, 2019 amounted to €35 094k. This amount does not include the research tax credit related to 2018, normally expected in Q4 which was received in February 2020.
In November 2019, Nanobiotix announced promising results from a pre-clinical immuno-oncology study of NBTXR3 at the 2019 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper). In the study, conducted at The University of Texas MD Anderson Cancer Center, researchers studied NBTXR3 activated by radiation therapy in combination with anti-PD-1 treatment in immunocompetent mice. Combination treatment that included NBTXR3 and anti-PD-1 increased local control of the irradiated tumor, generated a marked abscopal effect, decreased the number of spontaneous lung metastases, and significantly increased survival when compared to other treatments in the study, including anti-PD-1 combined with radiation therapy alone. The results indicated that the combination treatment has the potential to achieve an equivalent abscopal effect at a lower dose of radiation.
The study also included an in vivo RadScopal model in which a second tumor received a low dose of radiation while the first tumor received a full dose. In this model, researchers evaluated NBTXR3 activated by radiation therapy combined with anti-PD-1 and anti-CTLA-4 treatment. In the study, combination treatment triggered better local control, along with significant increases in abscopal effect and survival, when compared to all other tested combinations. Several complete responses were observed in the second tumor of the group that received the NBTXR3 combination, while none were observed in the other groups. Nanobiotix believes these results could pave the way for the use of NBTXR3 to improve treatment outcomes for immunooncology patients, including checkpoint inhibitor non-responders.
On December 16th 2019, Nanobiotix received the French 2019 Prix Galien award for Most Innovative MedTech. This award recognizes outstanding biomedical and medical technology product achievements that improve the human condition.
2020 Financial agenda
Nanobiotix plans to announce its financial and operating results as follows:
March 13, 2020 – 2019 Annual results
April 28, 2020 – Annual General Meeting, Paris, France
April 30, 2020 – Revenue for Q1
July 17, 2020 – Revenue for Q2
September 4, 2020 – Half year results
October 23, 2020 – Revenue for Q3